We are live on ! Find out more
MTCR

Metacrine, Inc. Common Stock

Delisted

MTCR was delisted on the 8th of February, 2023.

31 hedge funds and large institutions have $3.83M invested in Metacrine, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 4

72% more capital invested

Capital invested by funds: $2.23M → $3.83M (+$1.61M)

0% more funds holding

Funds holding: 3131 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
31
Holders Change
Holders Change %
0%
% of All Funds
0.49%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
12
Reduced
4
Closed
8
Calls
$68K
Puts
Net Calls
+$68K
Net Calls Change
+$54K
Name Holding Trade Value Shares
Change
Change in
Stake
Barclays
26
Barclays
United Kingdom
$7K +$6.14K +11,710 New
Citigroup
27
Citigroup
New York
$2K +$1.56K +2,982 New
JP Morgan Chase
28
JP Morgan Chase
New York
$1K +$544 +1,038 New
VF
29
Virtu Financial
New York
-$82K -122,366 Closed
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
-$56K -84,442 Closed
EGM
31
Engineers Gate Manager
New York
-$55K -81,497 Closed
Millennium Management
32
Millennium Management
New York
-$48K -71,017 Closed
Jane Street
33
Jane Street
New York
-$47K -69,003 Closed
HF
34
HRT Financial
New York
-$15K -23,589 Closed
CIM
35
CIM Investment Management
Pennsylvania
-$13K -19,054 Closed
Simplex Trading
36
Simplex Trading
Illinois
-$1.29K -2,462 Closed
Wells Fargo
37
Wells Fargo
California
+$50 +96 +120%

MTCR Hedge Fund Activity: Q1 2022 in Review

31 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q1 2022, worth a combined $3.83M — up 72% from $2.23M a quarter earlier.

Fund positioning in MTCR was balanced in Q1 2022: 8 funds opened new positions, 8 closed out, 12 added to existing stakes and 4 trimmed.

The largest buyer was Arch Venture Management, opening a new position worth an estimated $1.54M. The largest seller was Goldman Sachs, cutting an estimated $102K.

  • 31 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $3.83M of Metacrine, Inc. Common Stock stock for Q1 2022, up 72% quarter-over-quarter.
  • 8 funds opened new Metacrine, Inc. Common Stock positions in Q1 2022 and 8 closed out, a net change of 0 holders.
  • The largest Metacrine, Inc. Common Stock buyer in Q1 2022 was Arch Venture Management, an estimated $1.54M added.
  • The largest Metacrine, Inc. Common Stock seller in Q1 2022 was Goldman Sachs, an estimated $102K sold.

Based on aggregated 13F filings for Q1 2022.